While some studies noted elevated serum concentrations in GC patients compared to healthy controls or those with benign gastric disease, no consistent association was found between serum Gal-3 levels and tumor characteristics, treatment response, or overall survival [121,122]. This evidence concerns the gene LGALS3 and neoplasm.